Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer

CANTATA investigators

Research output: Contribution to journalArticlepeer-review

78 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science